In short
Parkinson's research studies continued. Updated white papers discussed possible future research in other neurological conditions.
August's update covered two months, because July's was so short. Much of it dealt with other topics. The parts about brain research are set out here.
Papers on dementia and stroke recovery
Zhittya updated its white paper, a background document, on vascular dementia and Alzheimer's disease. The update said many people had asked about the dementia research study. It cited World Health Organization data that more than 55 million people worldwide live with dementia.
The stroke recovery white paper was also updated. The update said Zhittya had dosed several people recovering from stroke over the past four years and had seen improvements. The new version adds more recent material, including brain imaging work on blood flow after FGF-1 dosing.
The imaging study at Washington University in St. Louis was continuing.
Two months of participant comments
The update shared nine messages received between mid-June and mid-August, most of them from people with Parkinson's. It also noted that three years of participant comments have been gathered in one place.
The messages touched on walking, the use of a walker or cane, freezing while walking, balance, energy, fatigue, sleep, mental clarity, bowel function and blood pressure. One mentioned "off" time, the periods when Parkinson's symptoms return.
Not every report was positive. One participant wrote that his tremor was a little worse even as his energy rose. Another listed symptoms that had not changed, including dystonia (muscle cramping) in one foot, leg weakness, neuropathy and the senses of taste and smell.
One participant wrote that it took about 17 months after his first dose before he noticed any change at all.
Participant counts
Participants are dosed in groups the team calls cohorts. The August cohort was the 50th.
By this point, the team reported having dosed more than 250 people with Parkinson's, along with people with stroke, multiple sclerosis, autism and the rarer brain conditions PSP and MSA.
Dr. Jack Jacobs and the chief executive were scheduled to present data at RAADfest, a conference on aging and longevity, in Scottsdale, Arizona, in early September.
This summary covers the Parkinson's research in the August 2026 update. The complete update, including the other topics it covered, is below.
Read the complete August 2026 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.